Clinical Context
A 52-year-old patient with established moderate-to-severe rheumatoid arthritis presents to an outpatient infusion/ambulatory injection clinic for scheduled subcutaneous biologic therapy with the adalimumab biosimilar, idacio. The medication is billed per milligram using HCPCS Level II code Q5144 (Injection, adalimumab-aacf (idacio), biosimilar, 1 mg). The clinical workflow includes medication verification by a licensed nurse, informed consent confirmation, documentation of baseline vital signs and infection screening (temperature, review of tuberculosis and recent infection history), pre-filled syringe preparation or vial reconstitution if applicable, and subcutaneous administration in the clinic or observation area. The patient is observed for a short period for immediate injection reaction and provided with post-injection self-care instructions, scheduled for the next dose, and the encounter is documented in the medical record with lot number, expiration date, dose administered (mg), site of injection, and supervising provider.
Typical site of service is an outpatient clinic, physician office, or ambulatory injection center. This service may also occur in an ambulatory infusion center when given alongside other parenteral therapies.